Press release
September 8, 2026
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics, Inc. (KROS)
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to